Connection

PEDRO PIEDRA to Respiratory Syncytial Viruses

This is a "connection" page, showing publications PEDRO PIEDRA has written about Respiratory Syncytial Viruses.
Connection Strength

4.279
  1. Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults. Front Immunol. 2019; 10:706.
    View in: PubMed
    Score: 0.586
  2. Respiratory Syncytial Virus (RSV): Neutralizing Antibody, a Correlate of Immune Protection. Methods Mol Biol. 2016; 1442:77-91.
    View in: PubMed
    Score: 0.468
  3. A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age. J Infect Dis. 2016 Feb 01; 213(3):411-22.
    View in: PubMed
    Score: 0.455
  4. Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis. Arch Pediatr Adolesc Med. 2012 Aug; 166(8):700-6.
    View in: PubMed
    Score: 0.369
  5. Immunopathogenesis of respiratory syncytial virus bronchiolitis. J Infect Dis. 2007 May 15; 195(10):1532-40.
    View in: PubMed
    Score: 0.256
  6. Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats. Vaccine. 2025 May 22; 56:127183.
    View in: PubMed
    Score: 0.223
  7. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021 01; 9(1):21-32.
    View in: PubMed
    Score: 0.163
  8. Respiratory viruses are associated with serum metabolome among infants hospitalized for bronchiolitis: A multicenter study. Pediatr Allergy Immunol. 2020 10; 31(7):755-766.
    View in: PubMed
    Score: 0.159
  9. Association of respiratory viruses with serum metabolome in infants with severe bronchiolitis. Pediatr Allergy Immunol. 2019 12; 30(8):848-851.
    View in: PubMed
    Score: 0.150
  10. RSV Strains and Disease Severity. J Infect Dis. 2019 01 29; 219(4):514-516.
    View in: PubMed
    Score: 0.145
  11. Respiratory Syncytial Virus and Rhinovirus Bronchiolitis Are Associated With Distinct Metabolic Pathways. J Infect Dis. 2018 03 13; 217(7):1160-1169.
    View in: PubMed
    Score: 0.136
  12. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J. 1998 Mar; 17(3):217-24.
    View in: PubMed
    Score: 0.136
  13. Detection of respiratory syncytial virus and rhinovirus in healthy infants. BMC Res Notes. 2015 Nov 25; 8:718.
    View in: PubMed
    Score: 0.116
  14. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016 01; 60(1):6-13.
    View in: PubMed
    Score: 0.115
  15. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26; 58(4):1630-43.
    View in: PubMed
    Score: 0.110
  16. Hospital length-of-stay is associated with rhinovirus etiology of bronchiolitis. Pediatr Infect Dis J. 2014 Aug; 33(8):829-34.
    View in: PubMed
    Score: 0.106
  17. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22; 111(16):5992-7.
    View in: PubMed
    Score: 0.104
  18. Mechanism of lung injury in cotton rats immunized with formalin-inactivated respiratory syncytial virus. Vaccine. 1989 Feb; 7(1):34-8.
    View in: PubMed
    Score: 0.072
  19. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine. 2003 Jun 02; 21(19-20):2448-60.
    View in: PubMed
    Score: 0.049
  20. Induction and regulation of nitric oxide synthase in airway epithelial cells by respiratory syncytial virus. Am J Respir Crit Care Med. 2001 Feb; 163(2):532-9.
    View in: PubMed
    Score: 0.042
  21. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics. 1999 Mar; 103(3):619-26.
    View in: PubMed
    Score: 0.036
  22. Serum LL-37 Levels Associated With Severity of Bronchiolitis and Viral Etiology. Clin Infect Dis. 2017 Sep 15; 65(6):967-975.
    View in: PubMed
    Score: 0.033
  23. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. J Virol. 2016 08 15; 90(16):7508-7518.
    View in: PubMed
    Score: 0.030
  24. Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in the Gambia and in The United States. Clin Diagn Lab Immunol. 1996 Jul; 3(4):477-9.
    View in: PubMed
    Score: 0.030
  25. Children Hospitalized with Rhinovirus Bronchiolitis Have Asthma-Like?Characteristics. J Pediatr. 2016 05; 172:202-204.e1.
    View in: PubMed
    Score: 0.029
  26. Absence of Bordetella pertussis Among Infants Hospitalized for Bronchiolitis in Finland, 2008-2010. Pediatr Infect Dis J. 2016 Feb; 35(2):219-21.
    View in: PubMed
    Score: 0.029
  27. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J. 1996 Jan; 15(1):23-31.
    View in: PubMed
    Score: 0.029
  28. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 1995 Sep; 16(3):393-9.
    View in: PubMed
    Score: 0.029
  29. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis. 1994 Jun; 169(6):1368-73.
    View in: PubMed
    Score: 0.026
  30. Immune response to experimentally induced infection with respiratory syncytial virus: possible role in the development of pulmonary disease. J Gen Virol. 1989 Feb; 70 ( Pt 2):325-33.
    View in: PubMed
    Score: 0.018
  31. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol. 1996 Jul; 34(7):1649-53.
    View in: PubMed
    Score: 0.008
  32. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr. 1994 Oct; 125(4):635-41.
    View in: PubMed
    Score: 0.007
  33. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J Pediatr. 1990 Aug; 117(2 Pt 1):313-20.
    View in: PubMed
    Score: 0.005
  34. Effect of respiratory syncytial virus infection on the uptake of and immune response to other inhaled antigens. Proc Soc Exp Biol Med. 1988 Jun; 188(2):191-7.
    View in: PubMed
    Score: 0.004
  35. Modulation of systemic and mucosal immune responses to inhaled ragweed antigen in experimentally induced infection with respiratory syncytial virus implication in virally induced allergy. Int Arch Allergy Appl Immunol. 1988; 86(1):112-6.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.